In addition, synthetic-lethal combinations (e.g., pairing MDH1 blockade with oxidative-stress inducers) warrant pre-clinical evaluation to exploit metabolic vulnerabilities unique to cancer cells while sparing normal tissues. Here, MDH1 is linked to cancer.